These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Unbiased Quantitation of Alveolar Type II to Alveolar Type I Cell Transdifferentiation during Repair after Lung Injury in Mice. Jansing NL; McClendon J; Henson PM; Tuder RM; Hyde DM; Zemans RL Am J Respir Cell Mol Biol; 2017 Nov; 57(5):519-526. PubMed ID: 28586241 [TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism. Murray JC; Symonds P; Ward W; Huggins M; Tiga A; Rice K; Heng YM; Todd I; Robins RA J Immunol; 2004 Jan; 172(1):274-81. PubMed ID: 14688335 [TBL] [Abstract][Full Text] [Related]
5. Low-Dose Endothelial Monocyte-Activating Polypeptide-II Increases Blood-Tumor Barrier Permeability by Activating the RhoA/ROCK/PI3K Signaling Pathway. Li Z; Liu XB; Liu YH; Xue YX; Liu J; Teng H; Xi Z; Yao YL J Mol Neurosci; 2016 Jun; 59(2):193-202. PubMed ID: 26521255 [TBL] [Abstract][Full Text] [Related]
6. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. Murray JC; Heng YM; Symonds P; Rice K; Ward W; Huggins M; Todd I; Robins RA J Leukoc Biol; 2004 May; 75(5):772-6. PubMed ID: 14982944 [TBL] [Abstract][Full Text] [Related]
7. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. Tsai BM; Wang M; Clauss M; Sun P; Meldrum DR Am J Physiol Regul Integr Comp Physiol; 2004 Oct; 287(4):R767-71. PubMed ID: 15155281 [TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I stimulates differentiation of ATII cells to ATI-like cells through activation of Wnt5a. Ghosh MC; Gorantla V; Makena PS; Luellen C; Sinclair SE; Schwingshackl A; Waters CM Am J Physiol Lung Cell Mol Physiol; 2013 Aug; 305(3):L222-8. PubMed ID: 23709620 [TBL] [Abstract][Full Text] [Related]
9. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516 [TBL] [Abstract][Full Text] [Related]
10. Vascular mediators in chronic lung disease of infancy: role of endothelial monocyte activating polypeptide II (EMAP II). Lal CV; Schwarz MA Birth Defects Res A Clin Mol Teratol; 2014 Mar; 100(3):180-8. PubMed ID: 24619875 [TBL] [Abstract][Full Text] [Related]
11. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. Schwarz MA; Kandel J; Brett J; Li J; Hayward J; Schwarz RE; Chappey O; Wautier JL; Chabot J; Lo Gerfo P; Stern D J Exp Med; 1999 Aug; 190(3):341-54. PubMed ID: 10430623 [TBL] [Abstract][Full Text] [Related]
12. Transdifferentiation of alveolar epithelial type II to type I cells is controlled by opposing TGF-β and BMP signaling. Zhao L; Yee M; O'Reilly MA Am J Physiol Lung Cell Mol Physiol; 2013 Sep; 305(6):L409-18. PubMed ID: 23831617 [TBL] [Abstract][Full Text] [Related]
13. Defining signals that promote human alveolar type I differentiation. Li Y; Prakash YS; Tan Q; Tschumperlin D Am J Physiol Lung Cell Mol Physiol; 2024 Apr; 326(4):L409-L418. PubMed ID: 38349124 [TBL] [Abstract][Full Text] [Related]
14. Coexpression of RTI40 with alveolar epithelial type II cell proteins in lungs following injury: identification of alveolar intermediate cell types. Clegg GR; Tyrrell C; McKechnie SR; Beers MF; Harrison D; McElroy MC Am J Physiol Lung Cell Mol Physiol; 2005 Sep; 289(3):L382-90. PubMed ID: 15849211 [TBL] [Abstract][Full Text] [Related]
15. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature. Kayton ML; Libutti SK Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006 [TBL] [Abstract][Full Text] [Related]
16. Low-dose endothelial monocyte-activating polypeptide-II increases permeability of blood-tumor barrier via a PKC-ζ/PP2A-dependent signaling mechanism. Li Z; Liu YH; Liu XB; Xue YX; Wang P; Liu LB Exp Cell Res; 2015 Feb; 331(2):257-66. PubMed ID: 25592443 [TBL] [Abstract][Full Text] [Related]
17. Breaking the in vitro alveolar type II cell proliferation barrier while retaining ion transport properties. Bove PF; Dang H; Cheluvaraju C; Jones LC; Liu X; O'Neal WK; Randell SH; Schlegel R; Boucher RC Am J Respir Cell Mol Biol; 2014 Apr; 50(4):767-76. PubMed ID: 24191670 [TBL] [Abstract][Full Text] [Related]
18. Enolase 1 (ENO1) and protein disulfide-isomerase associated 3 (PDIA3) regulate Wnt/β-catenin-driven trans-differentiation of murine alveolar epithelial cells. Mutze K; Vierkotten S; Milosevic J; Eickelberg O; Königshoff M Dis Model Mech; 2015 Aug; 8(8):877-90. PubMed ID: 26035385 [TBL] [Abstract][Full Text] [Related]
19. Potential role for antiangiogenic proteins in the evolution of bronchopulmonary dysplasia. Quintos-Alagheband ML; White CW; Schwarz MA Antioxid Redox Signal; 2004 Feb; 6(1):137-45. PubMed ID: 14713345 [TBL] [Abstract][Full Text] [Related]
20. Signal mechanisms underlying low-dose endothelial monocyte-activating polypeptide-II-induced opening of the blood-tumor barrier. Li Z; Liu YH; Xue YX; Liu LB; Wang P J Mol Neurosci; 2012 Sep; 48(1):291-301. PubMed ID: 22531886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]